Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All metformin studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchMetforminMetformin (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Risk of Post-Acute Sequelae of SARS-CoV-2 Infection (PASC) Among Patients with Type 2 Diabetes Mellitus on Anti-Hyperglycemic Medications

Olawore et al., Clinical Epidemiology, doi:10.2147/CLEP.S458901
May 2024  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
PASC, 6 months 19% Improvement Relative Risk PASC, 3 months 14% Metformin for COVID-19  Olawore et al.  Prophylaxis Is prophylaxis with metformin beneficial for COVID-19? Retrospective 7,047 patients in the USA (October 2021 - April 2023) Lower PASC with metformin (not stat. sig., p=0.29) c19early.org Olawore et al., Clinical Epidemiology, May 2024 Favorsmetformin Favorscontrol 0 0.5 1 1.5 2+
Metformin for COVID-19
3rd treatment shown to reduce risk in July 2020
 
*, now with p < 0.00000000001 from 91 studies.
No treatment is 100% effective. Protocols combine treatments. * >10% efficacy, ≥3 studies.
4,300+ studies for 77 treatments. c19early.org
Retrospective 7,047 outpatients with type 2 diabetes showing a lower risk of PASC (long COVID) with metformin compared to sulfonylurea or DPP-4 inhibitor use, without statistical significance.
risk of PASC, 19.0% lower, RR 0.81, p = 0.29, treatment 5,596, control 1,451, 6 months.
risk of PASC, 14.0% lower, RR 0.86, p = 0.50, treatment 5,596, control 1,451, 3 months.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Olawore et al., 31 May 2024, retrospective, USA, peer-reviewed, 8 authors, study period October 2021 - April 2023. Contact: oolawore@unc.edu.
This PaperMetforminAll
Risk of Post-Acute Sequelae of SARS-CoV-2 Infection (PASC) Among Patients with Type 2 Diabetes Mellitus on Anti-Hyperglycemic Medications
Oluwasolape Olawore, Lindsey E Turner, Michael D Evans, Steven G Johnson, Jared D Huling, Carolyn T Bramante, John B Buse, Til Stürmer
Clinical Epidemiology, doi:10.2147/clep.s458901
Background: Observed activity of metformin in reducing the risk of severe COVID-19 suggests a potential use of the antihyperglycemic in the prevention of post-acute sequelae of SARS-CoV-2 infection (PASC). We assessed the 3-month and 6-month risk of PASC among patients with type 2 diabetes mellitus (T2DM) comparing metformin users to sulfonylureas (SU) or dipeptidyl peptidase-4 inhibitors (DPP4i) users. Methods: We used de-identified patient level electronic health record data from the National Covid Cohort Collaborative (N3C) between October 2021 and April 2023. Participants were adults ≥ 18 years with T2DM who had at least one outpatient healthcare encounter in health institutions in the United States prior to COVID-19 diagnosis. The outcome of PASC was defined based on the presence of a diagnosis code for the illness or using a predicted probability based on a machine learning algorithm. We estimated the 3-month and 6-month risk of PASC and calculated crude and weighted risk ratios (RR), risk differences (RD), and differences in mean predicted probability. Results: We identified 5596 (mean age: 61.1 years; SD: 12.6) and 1451 (mean age: 64.9 years; SD 12.5) eligible prevalent users of metformin and SU/DPP4i respectively. We did not find a significant difference in risk of PASC at 3 months (RR = 0.86 [0.56; 1.32], RD = -3.06 per 1000 [-12.14; 6.01]), or at 6 months (RR = 0.81 [0.55; 1.20], RD = -4.91 per 1000 [-14.75, 4.93]) comparing prevalent users of metformin to prevalent users of SU/ DPP4i. Similar observations were made for the outcome definition using the ML algorithm. Conclusion: The observed estimates in our study are consistent with a reduced risk of PASC among prevalent users of metformin, however the uncertainty of our confidence intervals warrants cautious interpretations of the results. A standardized clinical definition of PASC is warranted for thorough evaluation of the effectiveness of therapies under assessment for the prevention of PASC. Plain Language Summary: Previous research suggests that metformin, due to its anti-viral, anti-inflammatory, and anti-thrombotic properties may reduce the risk of severe COVID-19. Given the shared etiology of COVID-19 and the post-acute sequelae of SARS-CoV-2 (PASC), and the proposed inflammatory processes of PASC, metformin may also be a beneficial preventive option. We investigated the benefit of metformin for PASC prevention in a population of type 2 diabetes mellitus patients with a COVID-19 diagnosis who were on metformin or two other anti-hyperglycemic medications prior to infection with SARS-CoV-2. Our results were consistent with a reduction in the risk of PASC with the use of metformin, however, the imprecise confidence intervals obtained warrants further investigation of this association of the potential beneficial effect of metformin for preventing PASC in patients with medication-managed diabetes.
Abbreviations DPP4i, Dipeptidyl Peptidase-4 Inhibitors; EHR, Electronic Health Record, ICD-10, International Classification of Diseases, 10 th Revision; ML, Machine Learning; N3C, Covid Cohort Collaborative; PASC, Post-acute Sequelae of SARS-CoV-2; RD, Risk Difference; RR, Risk Ratio; SU, Sulfonylurea; T2DM, Type 2 Diabetes Mellitus. Author Contributions All authors made a significant contribution to the work reported, whether that is in the conception, study design, execution, acquisition of data, analysis, and interpretation, or in all these areas; took part in drafting, revising or critically reviewing the article; gave final approval of the version to be published; have agreed on the journal to which the article has been submitted; and agree to be accountable for all aspects of the work. Disclosure JBB reports contracted fees and travel support for contracted activities for consulting work paid to the University of North Carolina by Novo Nordisk; grant support by Bayer, Boehringer-Ingelheim, Carmot, Corcept, Dexcom, Eli Lilly, Insulet, MannKind, Novo Nordisk, and vTv Therapeutics; consulting fees from Alkahest, Altimmune, Anji, Aqua Medical Inc, AstraZeneca, Bayer, Biomea Fusion Inc, Boehringer-Ingelheim, CeQur, Corcept Therapeutics, Eli Lilly, embecta, Fortress Biotech, GentiBio, Glycadia, Glyscend, Janssen, MannKind, Insulet, Mediflix, Medscape, Medtronic/ MiniMed, Mellitus Health, Metsera, Moderna, Pendulum Therapeutics, Praetego, ReachMD, Sanofi, Stability Health,..
References
Aiyegbusi, Hughes, Turner, Symptoms, complications and management of long COVID: a review, J R Soc Med, doi:10.1177/01410768211032850
Al-Aly, Bowe, Xie, Long COVID after breakthrough SARS-CoV-2 infection, Nat Med, doi:10.1038/s41591-022-01840-0
Al-Aly, Xie, Bowe, High-dimensional characterization of post-acute sequelae of COVID-19, Nature, doi:10.1038/s41586-021-03553-9
Ayoubkhani, Bosworth, King, Risk of Long COVID in people infected with severe acute respiratory syndrome Coronavirus 2 After 2 Doses of a Coronavirus Disease 2019 Vaccine: community-based, matched cohort study, Open Forum Infect Dis, doi:10.1093/ofid/ofac464
Bramante, Beckman, Metformin reduces SARS-CoV-2 in a Phase 3 randomized placebo controlled clinical trial, medRxiv
Bramante, Buse, Liebovitz, Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial, Lancet Infect Dis, doi:10.1016/S1473-3099(23)00299-2
Bramante, Huling, Tignanelli, Randomized Trial of Metformin, Ivermectin, and Fluvoxamine for Covid-19, N Engl J Med, doi:10.1056/NEJMoa2201662
Bramante, Johnson, Garcia, Diabetes medications and associations with Covid-19 outcomes in the N3C database: a national retrospective cohort study, PLoS One, doi:10.1371/journal.pone.0271574
Brand, Saarelainen, Sonajalg, Metformin in pregnancy and risk of adverse long-term outcomes: a register-based cohort study, BMJ Open Diabetes Res Care, doi:10.1136/bmjdrc-2021-002363
Brannock, Chew, Preiss, Long COVID risk and pre-COVID vaccination in an EHR-based cohort study from the RECOVER program, Nature Commun
Chan, Casiraghi, Laraway, Metformin is associated with reduced COVID-19 severity in patients with prediabetes, Diabet Res Clin Pract, doi:10.1016/j.diabres.2022.110157
Cutler, The Costs of Long COVID, JAMA Health Forum, doi:10.1001/jamahealthforum.2022.1809
Erickson, Fenno, Barzilai, Metformin for Treatment of Acute COVID-19: Systematic review of clinical trial data against SARS-CoV-2, Diabetes Care, doi:10.2337/dc22-2539
Feig, Donovan, Zinman, Metformin in women with type 2 diabetes in pregnancy (MiTy): a multicentre, international, randomised, placebo-controlled trial, Lancet Diabetes Endocrinol, doi:10.1016/S2213-8587(20)30310-7
Gordon, Subbian, Kibbe, Hernandez, Beasley et al., The Clinical & Translational Science Collaborative of Cleveland (CTSC) • Charleston Area Medical Center -U54GM104942
Groff, Sun, Ssentongo, Short-term and Long-term Rates of Postacute Sequelae of SARS-CoV-2 Infection: a Systematic Review, JAMA Net Open, doi:10.1001/jamanetworkopen.2021.28568
Haendel, Chute, Bennett, The National COVID Cohort Collaborative (N3C): Rationale, design, infrastructure, and deployment, J Am Med Inform Assoc, doi:10.1093/jamia/ocaa196
Hainmueller, Entropy balancing for causal effects: A Multivariate reweighting method to produce balanced samples in observational studies, Political Anal, doi:10.1093/pan/mpr025
Khullar, Zhang, Zang, Racial/Ethnic Disparities in Post-acute Sequelae of SARS-CoV-2 Infection in New York: an EHR-Based Cohort Study from the RECOVER Program, Clinical Epidemiology, doi:10.1007/s11606-022-07997-1
Khunti, Prato, Mathieu, Kahn, Gabbay et al., COVID-19, Hyperglycemia, and New-Onset Diabetes, Diabetes Care, doi:10.2337/dc21-1318
Lin, Gagne, Longitudinal data discontinuity in electronic health records and consequences for medication effectiveness studies, doi:10.1002/cpt.2400
Lopez, Hart, Katz, Racial and Ethnic Health Disparities Related to COVID-19, JAMA, doi:10.1001/jama.2020.26443
Lopez-Leon, Wegman-Ostrosky, Perelman, More than 50 long-term effects of COVID-19: a systematic review and meta-analysis, Scientific Rep
Mccarthy, Metformin as a potential treatment for COVID-19, Expert Opin Pharm, doi:10.1080/14656566.2023.2215385
Nassar, Daoud, Nso, Diabetes Mellitus and COVID-19: Review Article, Diabetes Metab Syndr, doi:10.1016/j.dsx.2021.102268
Parotto, Gyöngyösi, Howe, Post-acute sequelae of COVID-19: understanding and addressing the burden of multisystem manifestations, Lancet Respir Med, doi:10.1016/S2213-2600(23)00239-4
Parthasarathy, Tandel, Siddiqui, Harshan, Metformin suppresses SARS-CoV-2 in cell culture, Virus Res, doi:10.1016/j.virusres.2022.199010
Pfaff, Girvin, Bennett, Identifying who has long COVID in the USA: a machine learning approach using N3C data, Lancet Digit Health, doi:10.1016/S2589-7500(22)00048-6
Rizvi, Kathuria, Mahmeed, Post-COVID syndrome, inflammation, and diabetes, J Diabetes Complicat, doi:10.1016/j.jdiacomp.2022.108336
Simon, Luginbuhl, Parker, Reduced Incidence of Long-COVID Symptoms Related to Administration of COVID-19 Vaccines Both Before COVID-19 diagnosis and up to 12 weeks after, Clinical Epidemiology, doi:10.2147/CLEP.S458901DovePress
Soliman, Sanctis, Alaaraj, Hamed, The clinical application of metformin in children and adolescents: a short update, Acta Bio Medica
Subramanian, Nirantharakumar, Hughes, Symptoms and risk factors for long COVID in non-hospitalized adults, Nature Med, doi:10.1038/s41591-022-01909-w
Tandon, Abrams, Avula, Unraveling Links between Chronic Inflammation and Long COVID: workshop report, J Immunol, doi:10.4049/jimmunol.2300804
Thaweethai, Jolley, Karlson, Development of a definition of postacute sequelae of SARS-CoV-2 Infection, JAMA, doi:10.1001/jama.2023.8823
Ventura-López, Cervantes-Luevano, Aguirre-Sánchez, Treatment with metformin glycinate reduces SARS-CoV-2 viral load: an in vitro model and randomized, double-blind, Phase IIb clinical trial, Biomed Pharm, doi:10.1016/j.biopha.2022.113223
Wong, Hall, Vaddavalli, Glycemic control and clinical outcomes in U.S. Patients With COVID-19: data From the National COVID Cohort Collaborative (N3C) Database, Diab Care, doi:10.2337/dc21-2186
Wong, Lam, Bramante, Does COVID-19 Infection Increase the Risk of Diabetes?, Curr Evid Curr Diab Rep, doi:10.1007/s11892-023-01515-1
Wu, Ailshire, Crimmins, Mitrosz, Szakiel et al., Long COVID and symptom trajectory in a representative sample of Americans in the first year of the pandemic, Sci Rep, doi:10.1038/s41598-021-99269-x
Xian, Liu, Nilsson, Metformin inhibition of mitochondrial ATP and DNA synthesis abrogates NLRP3 inflammasome activation and pulmonary inflammation, Immunity, doi:10.1016/j.immuni.2021.05.004
{ 'indexed': {'date-parts': [[2024, 6, 1]], 'date-time': '2024-06-01T00:29:56Z', 'timestamp': 1717201796339}, 'reference-count': 40, 'publisher': 'Informa UK Limited', 'license': [ { 'start': { 'date-parts': [[2024, 5, 1]], 'date-time': '2024-05-01T00:00:00Z', 'timestamp': 1714521600000}, 'content-version': 'unspecified', 'delay-in-days': 0, 'URL': 'https://creativecommons.org/licenses/by-nc/3.0/'}], 'content-domain': {'domain': [], 'crossmark-restriction': False}, 'DOI': '10.2147/clep.s458901', 'type': 'journal-article', 'created': {'date-parts': [[2024, 5, 31]], 'date-time': '2024-05-31T04:30:15Z', 'timestamp': 1717129815000}, 'page': '379-393', 'source': 'Crossref', 'is-referenced-by-count': 0, 'title': 'Risk of Post-Acute Sequelae of SARS-CoV-2 Infection (PASC) Among Patients with Type 2 Diabetes ' 'Mellitus on Anti-Hyperglycemic Medications', 'prefix': '10.2147', 'volume': 'Volume 16', 'author': [ { 'ORCID': 'http://orcid.org/0000-0002-8954-6426', 'authenticated-orcid': True, 'given': 'Oluwasolape', 'family': 'Olawore', 'sequence': 'first', 'affiliation': []}, {'given': 'Lindsey', 'family': 'Turner', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0001-7449-3993', 'authenticated-orcid': True, 'given': 'Michael', 'family': 'Evans', 'sequence': 'additional', 'affiliation': []}, {'given': 'Steven', 'family': 'Johnson', 'sequence': 'additional', 'affiliation': []}, {'given': 'Jared', 'family': 'Huling', 'sequence': 'additional', 'affiliation': []}, {'given': 'Carolyn', 'family': 'Bramante', 'sequence': 'additional', 'affiliation': []}, {'given': 'John', 'family': 'Buse', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0002-9204-7177', 'authenticated-orcid': True, 'given': 'Til', 'family': 'Stürmer', 'sequence': 'additional', 'affiliation': []}], 'member': '301', 'published-online': {'date-parts': [[2024, 5]]}, 'reference': [ { 'key': 'ref1', 'doi-asserted-by': 'publisher', 'first-page': 'e221809', 'DOI': '10.1001/jamahealthforum.2022.1809', 'volume': '3', 'author': 'Cutler', 'year': '2022', 'journal-title': 'JAMA Health Forum'}, { 'key': 'ref2', 'doi-asserted-by': 'publisher', 'first-page': '1461', 'DOI': '10.1038/s41591-022-01840-0', 'volume': '28', 'author': 'Al-Aly', 'year': '2022', 'journal-title': 'Nat Med'}, { 'key': 'ref3', 'doi-asserted-by': 'publisher', 'DOI': '10.1093/ofid/ofac464', 'volume': '9', 'author': 'Ayoubkhani', 'year': '2022', 'journal-title': 'Open Forum Infect Dis'}, { 'key': 'ref4', 'first-page': '21263608', 'volume': '2021', 'author': 'Simon', 'year': '2021', 'journal-title': 'medRxiv'}, { 'key': 'ref5', 'doi-asserted-by': 'publisher', 'first-page': '1706', 'DOI': '10.1038/s41591-022-01909-w', 'volume': '28', 'author': 'Subramanian', 'year': '2022', 'journal-title': 'Nature Med'}, { 'key': 'ref6', 'doi-asserted-by': 'publisher', 'first-page': 'e2128568', 'DOI': '10.1001/jamanetworkopen.2021.28568', 'volume': '4', 'author': 'Groff', 'year': '2021', 'journal-title': 'JAMA Net Open'}, { 'key': 'ref7', 'doi-asserted-by': 'publisher', 'first-page': '428', 'DOI': '10.1177/01410768211032850', 'volume': '114', 'author': 'Aiyegbusi', 'year': '2021', 'journal-title': 'J R Soc Med'}, { 'key': 'ref8', 'doi-asserted-by': 'crossref', 'first-page': '1', 'DOI': '10.1038/s41598-020-79139-8', 'volume': '11', 'author': 'Lopez-Leon', 'year': '2021', 'journal-title': 'Scientific Rep'}, { 'key': 'ref9', 'doi-asserted-by': 'publisher', 'first-page': '259', 'DOI': '10.1038/s41586-021-03553-9', 'volume': '594', 'author': 'Al-Aly', 'year': '2021', 'journal-title': 'Nature'}, { 'key': 'ref10', 'doi-asserted-by': 'crossref', 'first-page': '1', 'DOI': '10.1038/s41467-023-38388-7', 'volume': '14', 'author': 'Brannock', 'year': '2023', 'journal-title': 'Nature Commun'}, { 'key': 'ref11', 'doi-asserted-by': 'publisher', 'first-page': '1', 'DOI': '10.1038/s41598-021-99269-x', 'volume': '12', 'author': 'Wu', 'year': '2022', 'journal-title': 'Sci Rep'}, { 'key': 'ref12', 'doi-asserted-by': 'publisher', 'first-page': '1099', 'DOI': '10.2337/dc21-2186', 'volume': '45', 'author': 'Wong', 'year': '2022', 'journal-title': 'Diab Care'}, { 'key': 'ref13', 'doi-asserted-by': 'publisher', 'first-page': '102268', 'DOI': '10.1016/j.dsx.2021.102268', 'volume': '15', 'author': 'Nassar', 'year': '2021', 'journal-title': 'Diabetes Metab Syndr'}, { 'key': 'ref14', 'doi-asserted-by': 'publisher', 'first-page': '207', 'DOI': '10.1007/s11892-023-01515-1', 'volume': '23', 'author': 'Wong', 'year': '2023', 'journal-title': 'Curr Evid Curr Diab Rep'}, { 'key': 'ref15', 'doi-asserted-by': 'publisher', 'first-page': '2645', 'DOI': '10.2337/dc21-1318', 'volume': '44', 'author': 'Khunti', 'year': '2021', 'journal-title': 'Diabetes Care'}, { 'key': 'ref16', 'doi-asserted-by': 'publisher', 'first-page': '108336', 'DOI': '10.1016/j.jdiacomp.2022.108336', 'volume': '36', 'author': 'Rizvi', 'year': '2022', 'journal-title': 'J Diabetes Complicat'}, { 'key': 'ref17', 'doi-asserted-by': 'publisher', 'first-page': '1463', 'DOI': '10.1016/j.immuni.2021.05.004', 'volume': '54', 'author': 'Xian', 'year': '2021', 'journal-title': 'Immunity'}, { 'key': 'ref18', 'doi-asserted-by': 'publisher', 'first-page': '199010', 'DOI': '10.1016/j.virusres.2022.199010', 'volume': '323', 'author': 'Parthasarathy', 'year': '2023', 'journal-title': 'Virus Res'}, { 'key': 'ref19', 'doi-asserted-by': 'publisher', 'first-page': '113223', 'DOI': '10.1016/j.biopha.2022.113223', 'volume': '152', 'author': 'Ventura-López', 'year': '2022', 'journal-title': 'Biomed Pharm'}, { 'key': 'ref20', 'first-page': '23290989', 'volume': '2023', 'author': 'Bramante', 'year': '2023', 'journal-title': 'medRxiv'}, { 'key': 'ref21', 'doi-asserted-by': 'publisher', 'first-page': '1119', 'DOI': '10.1016/S1473-3099(23)00299-2', 'volume': '23', 'author': 'Bramante', 'year': '2023', 'journal-title': 'Lancet Infect Dis'}, { 'key': 'ref22', 'doi-asserted-by': 'publisher', 'first-page': '1432', 'DOI': '10.2337/dc22-2539', 'volume': '46', 'author': 'Erickson', 'year': '2023', 'journal-title': 'Diabetes Care'}, { 'key': 'ref23', 'doi-asserted-by': 'publisher', 'first-page': '1199', 'DOI': '10.1080/14656566.2023.2215385', 'volume': '24', 'author': 'MCCarthy', 'year': '2023', 'journal-title': 'Expert Opin Pharm'}, { 'key': 'ref24', 'doi-asserted-by': 'publisher', 'first-page': 'e0271574', 'DOI': '10.1371/journal.pone.0271574', 'volume': '17', 'author': 'Bramante', 'year': '2022', 'journal-title': 'PLoS One'}, { 'key': 'ref25', 'doi-asserted-by': 'publisher', 'first-page': '739', 'DOI': '10.1016/S2213-2600(23)00239-4', 'volume': '11', 'author': 'Parotto', 'year': '2023', 'journal-title': 'Lancet Respir Med'}, { 'key': 'ref26', 'doi-asserted-by': 'publisher', 'first-page': '505', 'DOI': '10.4049/jimmunol.2300804', 'volume': '212', 'author': 'Tandon', 'year': '2024', 'journal-title': 'J Immunol'}, { 'key': 'ref27', 'doi-asserted-by': 'publisher', 'first-page': '110157', 'DOI': '10.1016/j.diabres.2022.110157', 'volume': '194', 'author': 'Chan', 'year': '2022', 'journal-title': 'Diabet Res Clin Pract'}, { 'key': 'ref28', 'doi-asserted-by': 'publisher', 'first-page': '427', 'DOI': '10.1093/jamia/ocaa196', 'volume': '28', 'author': 'Haendel', 'year': '2021', 'journal-title': 'J Am Med Inform Assoc'}, { 'key': 'ref29', 'doi-asserted-by': 'publisher', 'first-page': 'e532', 'DOI': '10.1016/S2589-7500(22)00048-6', 'volume': '4', 'author': 'Pfaff', 'year': '2022', 'journal-title': 'Lancet Digit Health'}, { 'key': 'ref30', 'doi-asserted-by': 'publisher', 'first-page': '25', 'DOI': '10.1093/pan/mpr025', 'volume': '20', 'author': 'Hainmueller', 'year': '2012', 'journal-title': 'Political Anal'}, { 'key': 'ref31', 'doi-asserted-by': 'publisher', 'first-page': '599', 'DOI': '10.1056/NEJMoa2201662', 'volume': '387', 'author': 'Bramante', 'year': '2022', 'journal-title': 'N Engl J Med'}, { 'key': 'ref32', 'doi-asserted-by': 'publisher', 'first-page': 'e002363', 'DOI': '10.1136/bmjdrc-2021-002363', 'volume': '10', 'author': 'Brand', 'year': '2022', 'journal-title': 'BMJ Open Diabetes Res Care'}, { 'key': 'ref33', 'doi-asserted-by': 'publisher', 'first-page': '834', 'DOI': '10.1016/S2213-8587(20)30310-7', 'volume': '8', 'author': 'Feig', 'year': '2020', 'journal-title': 'Lancet Diabetes Endocrinol'}, { 'key': 'ref34', 'volume': '91', 'author': 'Soliman', 'year': '2020', 'journal-title': 'Acta Bio Medica'}, { 'key': 'ref35', 'unstructured': 'A clinical case definition of post COVID-19 condition by a Delphi ' 'consensus; 2021.'}, { 'key': 'ref36', 'doi-asserted-by': 'publisher', 'first-page': '1934', 'DOI': '10.1001/jama.2023.8823', 'volume': '329', 'author': 'Thaweethai', 'year': '2023', 'journal-title': 'JAMA'}, { 'key': 'ref37', 'doi-asserted-by': 'publisher', 'first-page': '1127', 'DOI': '10.1007/s11606-022-07997-1', 'volume': '38', 'author': 'Khullar', 'year': '2023', 'journal-title': 'J Gen Intern Med'}, { 'key': 'ref38', 'doi-asserted-by': 'publisher', 'first-page': '719', 'DOI': '10.1001/jama.2020.26443', 'volume': '325', 'author': 'Lopez', 'year': '2021', 'journal-title': 'JAMA'}, { 'key': 'ref39', 'doi-asserted-by': 'publisher', 'first-page': '915', 'DOI': '10.1093/aje/kwg231', 'volume': '158', 'author': 'Ray', 'year': '2003', 'journal-title': 'Am J Epidemiol'}, { 'key': 'ref40', 'doi-asserted-by': 'publisher', 'first-page': '243', 'DOI': '10.1002/cpt.2400', 'volume': '111', 'author': 'Joshua Lin', 'year': '2022', 'journal-title': 'Clin Pharmacol Ther'}], 'container-title': 'Clinical Epidemiology', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://www.dovepress.com/getfile.php?fileID=99617', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://www.dovepress.com/getfile.php?fileID=99617', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2024, 5, 31]], 'date-time': '2024-05-31T04:30:27Z', 'timestamp': 1717129827000}, 'score': 1, 'resource': { 'primary': { 'URL': 'https://www.dovepress.com/risk-of-post-acute-sequelae-of-sars-cov-2-infection-pasc-among-patient-peer-reviewed-fulltext-article-CLEP'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2024, 5]]}, 'references-count': 40, 'URL': 'http://dx.doi.org/10.2147/CLEP.S458901', 'relation': {}, 'ISSN': ['1179-1349'], 'subject': [], 'container-title-short': 'CLEP', 'published': {'date-parts': [[2024, 5]]}}
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit